- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03975036
Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody
June 2, 2019 updated by: Henan Cancer Hospital
Exploratory Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Hydrochloride Combined With Pd-1 Antibody: An Open-Label, Single-center, Single-arm Study
The main objective was to evaluate the safety and efficacy of anlotinib hydrochloride combined with pd-1 antibody second-line and above in the treatment of advanced solid tumors
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
To observe the beneficial population and adverse reactions of anlotinib hydrochloride combined with pd-1 in the treatment of patients with advanced solid tumor, and to explore the safe and effective drug treatment dose in the combined program, so that more patients with advanced tumor with poor prognosis can benefit from the combined program
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Recruiting
- Henan Cancer Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed the informed consent form prior to patient entry.
- There is at least one measurable lesion in the pathologically diagnosed advanced solid tumor, including non-small cell lung cancer, liver cancer, gastric cancer, colorectal cancer, pancreatic cancer, soft tissue sarcoma, malignant melanoma, gallbladder cancer, esophageal cancer, ovarian cancer, endometrial cancer and breast cancer
- ≥ 18 and ≤ 70 years of age.
- Eastern Cooperative Oncology Group(ECOG) performance status 0 or 1.
- Life expectancy of more than 3 months.
- Adequate hepatic, renal, heart, and hematologic functions: ANC ≥ 1.5×109/L, PLT ≥ 100×109/L, HB ≥ 90 g/L, TBIL ≤ 1.5×ULN, ALT or AST ≤ 2.5×ULN (or ≤ 5×ULN in patients with liver metastases), Serum Cr ≤ 1.5×ULN, Cr clearance ≥ 60 mL/min;Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (50%).
- Female subjects of child-bearing potential must agree to use contraceptive measures starting 1 week before the administration of the first dose of apatinib until 6 months after discontinuing study drug. Male subjects must agree to use contraceptive measures during the study and 6 months after last dose of study drug.
Exclusion Criteria:
- uncontrollable hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, despite optimal medical therapy), grade II The above myocardial ischemia or myocardial infarction, poor control of arrhythmia (including QTc interval male ≥ 450 ms, female ≥ 470 ms).
- Patients previously treated with anticancer therapies also have a Toxicity Level> 1 in NCI CTCAE.
- A variety of factors that affect oral absorption (such as inability to swallow, nausea, vomiting, chronic diarrhea, intestinal obstruction, etc.).
- Patients with gastrointestinal bleeding risk may not be included, including the following: (1) active peptic ulcer lesions and fecal occult blood (++); (2) history of melena and vomiting within 3 months; (3) ) For fecal occult blood (+) must be gastroscopy, clear whether the existence of gastrointestinal organic diseases.
- Coagulation dysfunction (INR> 1.5, PT> ULN + 4s or APTT> 1.5 ULN), with bleeding tendency or ongoing thrombolysis or anti-blood coagulation treatment.
- Long-term, unhealed wounds or fractures.
- Active bleeding, within 30 days after major surgery.
- Intracranial metastasis.
- Pregnant or lactating women.
- Cytotoxic drug treatment, radiotherapy within 3 weeks after treatment; had taken two or more targeted drugs, or into the group before the other three months have been taking other targeted drugs.
- Other malignant tumors in the past 3 years.
- The investigators believe there is any condition that may harm the subject or result in the subject's inability to meet or perform the research requirements.
- Huge metastasis / recurrence (tumor diameter> 5 cm)。
- Malignant pleural effusion or ascites, causing NCI CTCAE grading 2 or more people with dyspnea.
- Any allergy to apatinib should be excluded.
- Severe liver and kidney dysfunction (grade 4) patients should be excluded.
- Persons with a history of substance abuse who can not be abdicated or have mental disorders.
- According to the judgment of the researcher, there is a concomitant disease that seriously endangers the patient's safety or affects the patient in completing the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anlotinib&pd-1 antibody
Anlotinib 10mg/d,q.d.,p.o.&pd-1 antibody 200mg/d.q.3w.d.l.v
|
Anlotinib Hydrochloride Capsules
Other Names:
Pembrolizumabinjection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival (PFS)
Time Frame: up to 2 year
|
From date of randomization until the date of first documented progression or date of death from any cause
|
up to 2 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival(OS)
Time Frame: up to 2 year
|
From date of randomization until the date of death from any cause
|
up to 2 year
|
Objective Response Rate (ORR)
Time Frame: up to 1 year
|
From date of randomization until the date of death from any cause
|
up to 1 year
|
Disease Control Rate (DCR)
Time Frame: up to 1 year
|
Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1.
|
up to 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 8, 2019
Primary Completion (Anticipated)
June 8, 2020
Study Completion (Anticipated)
July 8, 2021
Study Registration Dates
First Submitted
May 23, 2019
First Submitted That Met QC Criteria
June 2, 2019
First Posted (Actual)
June 5, 2019
Study Record Updates
Last Update Posted (Actual)
June 5, 2019
Last Update Submitted That Met QC Criteria
June 2, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019093
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on Anlotinib
-
First People's Hospital of HangzhouChia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRecurrent High-grade GliomaChina
-
Peng YuanCompletedBreast Neoplasm | Antineoplastic Agents | AnlotinibChina
-
Peking Union Medical College HospitalRecruitingPheochromocytoma | ParagangliomaChina
-
Peking Union Medical College HospitalRecruitingParaganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, MalignantChina
-
First Hospital of Shijiazhuang CityUnknownCarcinoma | Non-small Cell Lung Cancer | Lung NeoplasmChina
-
Sun Yat-sen UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
First Hospital of Shijiazhuang CityUnknownCarcinoma | Small Cell Lung Cancer | Lung NeoplasmChina
-
Hunan Cancer HospitalFuzhou Pulmonary Hospital of Fujian; Chia Tai Tianqing Pharmaceutical Group...RecruitingSmall Cell Lung CancerChina
-
Peking Union Medical College HospitalRecruiting
-
Sun Yat-sen UniversityRecruitingSarcoma,Soft TissueChina